This is a working overview of peptide analogue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
=== Legal status === Olipudase alfa was approved for medical use in Japan in March 2022. In May 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Xenpozyme, intended for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency type A/B or type B. Xenpozyme was reviewed under the accelerated assessment program of the European Medicines Agency (EMA). The applicant for this medicinal product is Genzyme Europe BV. Olipudase alfa was approved for medical use in the European Union in June 2022.
==== Under test conditions ==== Variations in BV under test conditions are dominated by the metabolism of the individuals or species being tested. In particular differences in the essential amino acids (EAAs) species to species has a significant effect, although even minor variations in amino acid metabolism individual to individual have a large effect. The fine dependence on the individual's metabolism makes measurement of BV a vital tool in diagnosing some metabolic diseases.
The term metalloid has also been used for elements that exhibit metallic lustre and electrical conductivity, and that are amphoteric, such as arsenic, antimony, vanadium, chromium, molybdenum, tungsten, tin, lead, and aluminium. The p-block metals, and nonmetals (such as carbon or nitrogen) that can form alloys with metals or modify their properties have also occasionally been considered as metalloids.
=== Nerves === The reptilian nervous system contains the same basic part of the amphibian brain, but the reptile cerebrum and cerebellum are slightly larger. Most typical sense organs are well developed with certain exceptions, most notably the snake's lack of external ears (middle and inner ears are present). There are twelve pairs of cranial nerves. Due to their short cochlea, reptiles use electrical tuning to expand their range of audible frequencies.
Sources: en.wikipedia.org
Actin is used as an internal control in western blots to ascertain that equal amounts of protein have been loaded on each lane of the gel. In the blot example shown on the left side, 75 μg of total protein was loaded in each well. The blot was reacted with anti-β-actin antibody. The use of actin as an internal control is based on the assumption that its expression is practically constant and independent of experimental conditions. By comparing the expression of the gene of interest to that of the actin, it is possible to obtain a relative quantity that can be compared between different experiments, whenever the expression of the latter is constant. It is worth pointing out that actin does not always have the desired stability in its gene expression.
These drugs are expected to restore a normal libido in patients. Targeting acquired and generalized hypoactive sexual desire disorder (HSDD), improvement in sexual desire, and alleviation of psychological stress are to relieve the correlated symptoms. However, the treatments cannot cope with medically or psychiatrically related conditions, nor the effects from other medications.
sescent-kvindek-mil-kvadratkilometra (consisting of 650 000 square kilometers), 33 letters, used in an Esperanto version of a 2011 article by Marc Lavergne in Le Monde diplomatique, tragedio-komedio-historio-pastoraloj (tragical-comical-historical-pastorals), 33 letters, used in L. L. Zamenhof's 1893 translation of Hamlet, Nord-Atlantik-Traktad-Organizo (North Atlantic Treaty Organization), 27 letters, more commonly translated with two words: Nord-Atlantika Traktat-Organiz(aĵ)o.
Sources: en.wikipedia.org
The effects of 2C-B were reported by Shulgin to include sensory enhancement, brightened colors, visual richness, mental imagery, psychedelic visuals including kaleidoscopic and organic forms, sound distortion, increased appreciation of art and music, passivity, relaxation, emotional changes, euphoria, increased body awareness, tactile enhancement, feeling like waves of energy are flowing through oneself, feeling like one's body is flooded with orgasms, and sexual enhancement. He has succinctly described 2C-B as having "a luxury of sensory enhancement (visual, sexual, gustatory) with a minimum of introspective demands". The drug was one of his favorite psychedelics and one of his "magical half-dozen" most important psychedelic phenethylamines. At doses of 8 to 10 mg, 2C-B was described as consistently producing substantial sensory enhancement, but as not "superimposing hallucinogenesis" or as having "no hallucinogenic effects", with the state being described as quite distinct from that usually associated with psychedelics. It was also said to lack the lassitude that can be associated with psilocybin.
Acta Biochimica et Biophysica Sinica (ABBS) is a peer-reviewed scientific journal which publishes original research articles, short communications, and reviews in the fields of biochemistry and biophysics. Established in 1958, the journal is sponsored by the Institute of Biochemistry and Cell Biology, an institute of the Chinese Academy of Sciences, and is published monthly by Oxford Journals and was published by Blackwell Publishing prior to January 2009. This journal is indexed in the following databases: Science Citation Index Expanded Zoological Record BIOSIS Previews Chemical Abstracts Service – CASSI Index medicus MEDLINE PubMed
{\displaystyle {\begin{cases}{\ce {^{235}_{92}U + ^{1}_{0}n -> ^{236m}_{92}U ->[][120 \ {\ce {ns}}] ^{236}_{92}U + \gamma}}\\{\ce {^{236}_{92}U + ^{1}_{0}n -> ^{237}_{92}U ->[\beta^-][6.75 \ {\ce {d}}] ^{237}_{93}Np}}\end{cases}}}
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.